
The FDA approved Lucamzi (ranibizumab-blrz), Xbrane's Lucentis biosimilar, for wet AMD and other serious eye conditions, with a US launch planned for 2027.
Q3 2026 delivered advances in some closely watched pipeline products.
The third quarter of 2026 delivered some of the most closely watched retina approvals in years, a new entrant in the





